CD33*CD3 BsAb for Acute Myeloid Leukemia

"Affirmative, the clinical trial in question is open to participants. The initial posting date was May 25th 2022 with a most recent update taking place on November 18th of that same year. As many as 36 patients are needed between 13 various medical centres."

"Up to 36 minors between the ages of two and twenty-one suffering from acute myeloid leukemia may be admitted into this clinical trial. To qualify, they must present with a pathology confirming their relapsed or refractory AML (excluding APML), have ≥5% disease burden in their marrow, give informed consent as well as assent if required by local regulations, display adequate body weight (>11kg) and performance status scores according to age group (Karnofsky >50/ Lansky >50), WBC count ≤25 x 109/L, no signs or symptoms of cranial palsy nor any radiographic"

"Due to its Phase 1 status, the safety of CD33*CD3 BsAb was classified with a score of 1. This is on account of only minimal clinical data present in regards to efficacy and safety."

"This medical trial requires that participants are between the ages of 2 and 21."

"The trial is currently running at 13 different medical centres, including those in Boston, San Francisco and Pittsburgh. To minimize the amount of travel necessary to participate in this study, it's suggested that you choose a clinic located near your residence."

"36 willing and eligible patients are requested to participate in this study. Two of the approved sites for enrolling participants are Dana-Farber Cancer Institute (Boston, MA) and UCSF Benioff Children's Hospital (San Francisco, CA)."